Television personality and sports reporter Jay Glazer is opening up
about his personal experiences with attention-deficit/hyperactivity
disorder (ADHD) – one of the most common psychiatric diagnoses
affecting approximately 10 million adults in the U.S. – and with
Qelbree (viloxazine extended-release capsules), a nonstimulant
medication for the treatment of ADHD.3
Glazer, who has always been outspoken about his
mental health struggles, wants others to know that when it comes to
ADHD, there are many going through similar experiences. By gaining
a clear understanding of what ADHD is, common symptoms and how it
affects people’s day to day lives, individuals can work with their
doctors to choose the best course of action to suit their personal
needs.
“I’m partnering with Supernus to help others
overcome the stigmas associated with ADHD and help those diagnosed
understand they are not alone,” says Glazer. “I’ve struggled a lot
in my treatment journey. Since I was diagnosed later in life as an
adult, it has been difficult trying to find the right treatment.
Qelbree has helped me manage my ADHD symptoms, and I have Supernus
to thank for that.”
October is ADHD Awareness Month, an important time
to bring attention to the often complicated diagnosis and treatment
journey and an opportunity for individuals to learn, educate and
empower one another.
“Supernus stands with the ADHD community
year-round, and especially during ADHD Awareness Month, offering
solidarity, support and understanding for those living with the
condition,” says Jack A. Khattar, President and Chief Executive
Officer of Supernus Pharmaceuticals. “We’re thrilled to see the
impact that Qelbree has had on people living with ADHD, including
Jay Glazer, and appreciate his willingness to join us during this
important time of year and open up about his ADHD story of
perseverance and optimism.”
For more information about Qelbree, visit
Qelbree.com. Patients should speak to a doctor about all the
medications they take, and to see if Qelbree could be right for
them.
INDICATION
Qelbree® (viloxazine extended-release capsules) is
a prescription medicine used to treat ADHD in adults and children 6
years and older.
IMPORTANT SAFETY
INFORMATIONQelbree may increase suicidal thoughts
and actions, in children and adults with ADHD, especially within
the first few months of treatment or when the dose is changed. Tell
your doctor if you or your child have (or if there is a family
history of) suicidal thoughts or actions before starting Qelbree.
Monitor your or your child’s moods, behaviors, thoughts, and
feelings during treatment with Qelbree. Report any new or sudden
changes in these symptoms right away.
You should not take Qelbree if you or your
child: Take a medicine for depression called a monoamine
oxidase inhibitor (MAOI) or have stopped taking an MAOI in the past
14 days. Also, you or your child should avoid alosetron,
duloxetine, ramelteon, tasimelteon, tizanidine, and
theophylline.
Qelbree can increase blood pressure and
heart rate. Your or your child’s doctor will monitor these
vital signs.
Qelbree may cause manic episodes in
patients with bipolar disorder. Tell your doctor if you or
your child show any signs of mania.
Do not drive or operate heavy machinery
until you know how Qelbree will affect you or your child.
Qelbree may cause you or your child to feel sleepy or tired.
The most common side effects of
Qelbree in patients 6 to 17 years are sleepiness, not
feeling hungry, feeling tired, nausea, vomiting, trouble sleeping,
and irritability, and in adults, insomnia, headache, sleepiness,
tiredness, nausea, decreased appetite, dry mouth, and constipation.
These are not all the possible side effects of Qelbree.
You are encouraged to report negative side effects
of prescription drugs to the FDA. Visit www.fda.gov/medwatch or
call 1-800-FDA-1088.
Please see full Prescribing Information, including
Boxed Warning, for Qelbree here.
About Supernus Pharmaceuticals,
Inc.
Supernus Pharmaceuticals is a biopharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes
approved treatments for epilepsy, migraine, ADHD, hypomobility in
Parkinson’s disease (PD), cervical dystonia, chronic sialorrhea,
dyskinesia in PD patients receiving levodopa-based therapy, and
drug-induced extrapyramidal reactions in adult patients. We are
developing a broad range of novel CNS product candidates including
new potential treatments for hypomobility in PD, epilepsy,
depression, and other CNS disorders.
For more information, please visit
www.supernus.com.
1Centers for Disease Control and Prevention. Data
and Statistics About ADHD. Centers for Disease Control and
Prevention. https://www.cdc.gov/ncbddd/adhd/data.html.
2Castellanos, F. X. (2012). Large-Scale Brain
Systems in ADHD: Beyond the Prefrontal-Striatal Model. Trends in
Cognitive Science.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272832/.
3Culpepper, L., Mattingly, G. (2010). Challenges in
Identifying and Managing Attention-Deficit/Hyperactivity Disorder
in Adults in the Primary Care Setting: A Review of the Literature.
Primary Care Companion Journal of Clinical Psychiatry.
CONTACT:
Jack A. Khattar, President and CEOTimothy C. Dec,
Senior Vice President and CFOSupernus Pharmaceuticals, Inc.Tel:
(301) 838-2591
Or
MEDIA CONTACT:
Alice SofieldMobile: (703) 861-5654Email:
Alice.Sofield@BCW-Global.com
INVESTOR CONTACT:
Peter VozzoICR WestwickeOffice: (443)
213-0505Email: peter.vozzo@westwicke.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024